Last reviewed · How we verify

NCT01207050

Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury

Status unknown Phase 4 Last updated 8 September 2014
What this trial tests

Phase 4 trial testing Ramelteon in Insomnia in 20 participants. Status unknown.

Timeline
1 September 2010
Primary endpoint
1 December 2014
1 December 2014

Quick facts

Lead sponsorKessler Foundation
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment20
Start date1 September 2010
Primary completion1 December 2014
Estimated completion1 December 2014
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kessler Foundation

Who can join

18 and older, any sex, with Insomnia or Brain Injury. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This pilot study proposes to examine the effect of Rozerem on sleep/wake patterns among individuals with Traumatic Brain Injury (TBI) experiencing sleep disturbance, using both objective and subjective measures. It will also show that improvement in sleep/wake patterns resulting from Rozerem will impact daytime functioning using objective and subjective measures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ramelteon

Trials testing the same drug.

Other recruiting trials for Insomnia

Currently open trials in the same condition.

Other Kessler Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01207050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing